title: Oral antibiotic treatment and long-term outcomes of Lyme facial nerve palsy.
abstract: OBJECTIVE
  To study the long-term functional outcomes of patients with Lyme facial nerve palsy treated with oral antibiotics.
  
  
  METHODS
  We conducted a retrospective double-cohort study involving patients with Lyme facial nerve palsy treated with oral antibiotics matched to three controls with early localized Lyme disease. Chart review was completed and an SF-36 health questionnaire and standardized symptom questionnaire administered.
  
  
  RESULTS
  Lyme facial nerve palsy patients were treated with oral antibiotics for a median duration of 21 days (range 7-30 days). Only three patients underwent lumbar puncture and each demonstrated lymphocytic pleocytosis. Fourteen of 15 patients with Lyme facial nerve palsy completely regained nerve function. The long-term outcomes were similar between patients with Lyme facial nerve palsy and controls after a median follow-up duration of 4.6 years. Patients with Lyme facial nerve palsy had significantly higher reported rates of fatigue (60%) than controls (27%) (p = 0.019), but similar energy and vitality scores on the SF-36 questionnaire (55.0 vs. 58.4, p = 0.621). SF-36 social functioning domain scores were significantly lower in patients with Lyme facial nerve palsy (77.5) than in controls (88.6) (p = 0.044). There were no other significant differences noted between the two cohorts.
  
  
  CONCLUSIONS
  For patients with Lyme facial nerve palsy in North America, treatment with oral doxycycline appears to be an effective therapeutic strategy.
authors.affiliation: Section of Infectious Disease, Gundersen Lutheran Health System, 1900 South Avenue, La Crosse, WI 54601, USA. TJKowals@gundluth.org
authors.forename: T J
authors.initials: TJ
authors.lastname: Kowalski
authors.forename: W L
authors.initials: WL
authors.lastname: Berth
authors.forename: M A
authors.initials: MA
authors.lastname: Mathiason
authors.forename: W A
authors.initials: WA
authors.lastname: Agger
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004318:Doxycycline / Q000627:therapeutic use; D005155:Facial Nerve Diseases / Q000188:drug therapy*; D005158:Facial Paralysis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008134:Long-Term Care; D020852:Lyme Neuroborreliosis / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013129:Spinal Puncture; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D004318:Doxycycline